



9 Januari 2019  
9 January 2019  
P.U. (A) 8

WARTA KERAJAAN PERSEKUTUAN

*FEDERAL GOVERNMENT  
GAZETTE*

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2019

*POISONS (AMENDMENT OF POISONS LIST) ORDER 2019*

DISIARKAN OLEH/  
*PUBLISHED BY*  
JABATAN PEGUAM NEGARA/  
*ATTORNEY GENERAL'S CHAMBERS*

AKTA RACUN 1952

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2019

PADA menjalankan kuasa yang diberikan oleh seksyen 6 Akta Racun 1952 [*Akta 366*], Menteri, selepas berunding dengan Lembaga Racun, membuat perintah yang berikut:

**Nama**

1. Perintah ini bolehlah dinamakan **Perintah Racun (Pindaan Senarai Racun) 2019**.

**Pindaan Jadual Pertama**

2. Akta Racun 1952 dipinda dalam Jadual Pertama—

(a) dalam Senarai Racun—

- (i) dengan memasukkan selepas butiran “Adalimumab” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-APINACA)	-	All preparations				
N-(Adamantan-1-yl)-1-pentyl-1H-indazole-3-carboxamide (APINACA)	-	All preparations";				

- (ii) dengan memasukkan selepas butiran "Agomelatine" dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Albutrepenonacog alfa	-	All preparations";				

- (iii) dengan memasukkan selepas butiran "Amilsulpride" dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Amino acids, unless specified elsewhere in the List	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C
N- [(1S) - 1- (Aminocarbonyl) - 2- methylpropyl] - 1- (cyclohexylmethyl) 1H-indazole- 3- carboxamide (AB-CHMINACA)	-	All	preparations”;			

- (iv) dengan memasukkan selepas butiran “Anidulafungin” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"4-Anilino-N-phenethylpiperidine (ANPP)	-	-	-	-	All preparations";	

- (v) dengan memasukkan selepas butiran "Atenolol; its salts" dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Atezolizumab	-	All preparations";				

- (vi) dengan memasukkan selepas butiran "Bepiridil; its salts" dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Beroctocog alfa	-	All preparations";				

(vii) dengan memasukkan selepas butiran "Carfentanil citrate" dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Carfilzomib	-	All preparations";				

(viii) dengan memasukkan selepas butiran "Cyclofenil" dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"N-[[1-(Cyclohexylmethyl)-1H-indol-3yl]carbonyl]-3-methyl-L-valinate (MDMB-CHMICA)	-	All preparations";				

- (ix) dengan memasukkan selepas butiran "Dapsone" dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Daratumumab	-	All preparations";				

- (x) dengan memasukkan selepas butiran "Dipyrrone" dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Diquafosol	-	All preparations";				

- (xi) dengan memasukkan selepas butiran "Elaterin" dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Elbasvir	-	All preparations";				

- (xii) dengan memasukkan selepas butiran "Emepromium; its salts" dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Emodepside	-	-	All preparations";			

(xiii) dengan memasukkan selepas butiran "Eplerenone" dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Eprinomectin	-	All preparations";				

(xiv) dengan memasukkan selepas butiran "N-ethyl MDA (DD)" dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Ethylone (3,4-Methylenedioxy-N-ethylcathinone)	-	All preparations				
Ethylphenidate	-	All preparations”;				

- (xv) dengan memasukkan selepas butiran “[1-(5-fluoropentyl)-1H-indol-3-yl](naphthalen-1-yl)methanone (AM-2201)” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“[1-(5-Fluoropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR-11)	-	All preparations”;				

- (xvi) dengan memasukkan selepas butiran “Glucagon; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Glucose	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”;

- (xvii) dengan memasukkan selepas butiran “Granisetron; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Grazoprevir	-	All preparations”;				

(xviii) dengan memasukkan selepas butiran “8-[N-(2-hydroxyethyl)-methyl-amino]-1, 3, 7 trimethylxanthine” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Hydroxyethylstarch	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”;

(xix) dengan menggantikan butiran “Iodine” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Iodine	-	-	All preparations for parenteral administration. All medicinal	All preparations unless in Group C or	-	Preparations containing less than 2% of iodine

preparations exempted unless in  
 containing 2% and Group C”  
 above of iodine

(xx) dengan memasukkan selepas butiran “Methimazole; its salts” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Methiopropamine (MPA)	-	All preparations”;				

(xxi) dengan memasukkan selepas butiran “Methotrexate; its salts” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Methoxetamine (MXE)	-	All preparations”;				

(xxii) dengan memasukkan selepas butiran “N-Methylephedrine camsylate” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>	
“4-Methylethcathinone (4-MEC)	-	All preparations			
3- Methylmethcathinone (3-MMC)	-	All preparations			
Methyl 2-({[1-(5- fluoropentyl)-1H- indazol-3-yl] carbonyl}amino)-3- methylbutanoate (5F- AMB)	-	All preparations”;			

(xxiii) dengan memasukkan selepas butiran “Miltefosine” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Minerals; the following, unless specified elsewhere in the List:  Chromium Copper Fluorine Iron Manganese Selenium Zinc	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”;

(xxiv) dalam butiran “Narcotic substances, the following: their isomers (whenever the existence of such isomers is possible within the specific chemical designation); their salts; their esters and ethers (whenever the existence of such esters or ethers is possible); the salts of their esters and ethers—”—

- (A) dengan memasukkan selepas butiran “(DD) Acetyldihydrocodeine” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) Acetylfentanyl	-	All preparations”;				

- (B) dengan menggantikan butiran “(DD) 4-bromo-2,5-dimethoxyphenylethylamine (2C-B)” dan butir-butir yang berhubung dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) 4-bromo-2,5-dimethoxyphenethylamine (2C-B)	All preparations					
(DD) Butyrfentanyl	-	All preparations”;				

- (C) dengan memasukkan selepas butiran “(DD) Codoxime” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>	
“(DD) 1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45)	-	All preparations”;			

- (D) dengan memasukkan selepas butiran “(DD) Diampromide” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>	
“(DD) 3,4-Dichloro-N-[(1-dimethylamino) cyclohexylmethyl]benzamide (AH-7921)	-	All preparations			

(DD) 3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide  
(U-47700) - All preparations”;

(E) dengan menggantikan butiran “(DD) Remifentanil” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>	
“(DD) Remifentanil	-	All products registered under the Control of Drugs and Cosmetics Regulations 1984”;			

(xxv) dengan memasukkan selepas butiran “Nebivolol” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Necitumumab	-	All preparations";				

(xxvi) dengan memasukkan selepas butiran "Nialamide" dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Nicarbazin	-	All preparations";				

(xxvii) dengan memasukkan selepas butiran "Oseltamivir" dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Osimertinib	-	All preparations";				

(xxviii) dengan memasukkan selepas butiran “Paramethoxyamphetamine (PMA) (DD)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Para-methoxymethylamphetamine (PMMA) (DD)	-	All preparations				
Para-methyl-4-methylaminorex (4,4'-DMAR)	-	All preparations”;				

(xxix) dengan memasukkan selepas butiran “Pentazocine; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Pentedrone ( $\alpha$ -methylaminovalerophenone)	-	All preparations”;				

(xxx) dengan memasukkan selepas butiran “Phenethylamine unless specified elsewhere in the List” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“N-Phenethyl-4-piperidinone (NPP)	-	-	-	-	All preparations”;	

(xxxi) dengan memasukkan selepas butiran “Phenmetrazine; its salts” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Phenolphthalein	-	-	All preparations for therapeutic use	-	All preparations unless in Group C”;	

(xxxii) dengan memasukkan selepas butiran “Pyrovalerone” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“ $\alpha$ -Pyrrolidinovalerophenone ( $\alpha$ -PVP)	-	All preparations”;				

(xxxiii) dengan memasukkan selepas butiran “Quinine; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F-PB-22)	-	All preparations”;				

(xxxiv) dengan memasukkan selepas butiran “Rizatriptan; its salts” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Robenidine	-	All preparations”;				

(xxxv) dengan memasukkan selepas butiran “Styramate” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Succinylated gelatin	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”;

(xxxvi) dengan memasukkan selepas butiran “Triflusal” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>		<i>Part II</i>	<i>Exempt</i>		
	<i>Group A</i>	<i>Group B</i>			<i>Group C</i>	<i>Group D</i>
“Triglycerides	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”;

(xxxvii) dalam butiran “Vitamins, the following:”, dengan memasukkan selepas butiran “Mecobalamin” butiran “Menaquinone”; dan

(b) dalam Lampiran kepada Senarai Racun—

- (i) dalam senarai “**Anaesthetics**” dengan memasukkan selepas butiran “Local anaesthetics, the following: their salts; their homologues and analogues; their molecular compounds” butiran “Methoxetamine (MXE)”;
- (ii) dalam senarai “**Analeptics and Central Stimulants**”—

(A) dengan memasukkan selepas butiran “N-Ethyl MDA (DD)” butiran yang berikut:

“Ethylone (3,4-Methylenedioxy-N-ethylcathinone)  
Ethylphenidate”;

(B) dengan memasukkan selepas butiran “Methcathinone (DD)” butiran “Methiopropamine (MPA)”;

(C) dengan memasukkan selepas butiran “3, 4-Methylenedioxymetamphetamine (MDMA) (DD)” butiran yang berikut:

“4-Methylethcathinone (4-MEC)  
3- Methylmethcathinone (3-MMC)”;

(D) dengan memasukkan selepas butiran “Paramethoxyamphetamine (PMA) (DD)” butiran yang berikut:

“Para-methoxymethylamphetamine (PMMA) (DD)  
Para-methyl-4-methylaminorex (4,4'-DMAR)”;

(E) dengan memasukkan selepas butiran “Pemoline; its salts” butiran “Pentedrone ( $\alpha$ - methylaminovalerophenone)”;

(F) dengan memasukkan selepas butiran “Pyrovalerone” butiran “ $\alpha$ -Pyrrolidinovalerophenone ( $\alpha$ -PVP)”;

(iii) dalam senarai “**Analgesics including antipyretic and anti-inflammatory agents**”—

(A) dengan memasukkan selepas butiran “Acetanilide; alkylacetanilides” butiran yang berikut:

“N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-APINACA)  
N-(Adamantan-1-yl)-1-pentyl-1H-indazole-3-carboxamide (APINACA)”;

(B) dengan memasukkan selepas butiran “Amidopyrine; its salts” butiran “N- [(1S) - 1- (Aminocarbonyl) - 2-methylpropyl] - 1- (cyclohexylmethyl) 1H- indazole- 3- carboxamide (AB-CHMINACA)”;

(C) dengan memasukkan selepas butiran “Cinchophen and other substances structurally derived from 4 quinolinecarboxylic acid unless specified elsewhere in the list; their salts and esters” butiran “N-{{[1-(Cyclohexylmethyl)-1H-indol-3yl]carbonyl}-3-methyl-L-valinate (MDMB-CHMICA)”;

(D) dengan memasukkan selepas butiran “Flunixin” butiran “[1-(5-Fluoropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl) methanone (XLR-11)”;

(E) dengan memasukkan selepas butiran “Mesalazine” butiran “Methyl 2-({[1-(5-fluoropentyl)-1H-indazol-3-yl] carbonyl}amino)-3-methylbutanoate (5F-AMB)”;

- (F) dengan memasukkan selepas butiran “Proquazone” butiran “Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F-PB-22)”;
- (iv) dalam senarai “**Anthelmintics**” dengan memasukkan selepas butiran “Doramectin” butiran “Emodepside”;
- (v) dalam senarai “**Antifungals and Antiprotozoals**”—
  - (A) dengan memasukkan selepas butiran “Natamycin” butiran “Nicarbazin”; dan
  - (B) dengan memasukkan selepas butiran “Posaconazole” butiran “Robenidine”;
- (vi) dalam senarai “**Antineoplastic agents and Immunosuppressants**”—
  - (A) dengan memasukkan selepas butiran “L-Asparaginase” butiran “Atezolizumab”;
  - (B) dengan memasukkan selepas butiran “Carboplatin” butiran “Carfilzomib”;
  - (C) dengan memasukkan selepas butiran “Dacliximab” butiran “Daratumumab”;
  - (D) dengan memasukkan selepas butiran “Natalizumab” butiran “Necitumumab”; dan

- (E) dengan memasukkan selepas butiran “Orthopterin” butiran “Osimertinib”;
- (vii) dalam senarai “**Antiviral agents**”—
- (A) dengan memasukkan selepas butiran “Efavirenz” butiran “Elbasvir”; dan
  - (B) dengan memasukkan selepas butiran “Ganciclovir” butiran “Grazoprevir”;
- (viii) dalam senarai “**Narcotics**”—
- (A) dengan memasukkan selepas butiran “(DD) Acetyldihydrocodeine” butiran “(DD) Acetylfentanyl”;
  - (B) dengan memasukkan selepas butiran “(DD) 4-bromo-2, 5-dimethoxyphenethylamine (2C-B)” butiran “(DD)Butyrfentanyl”;
  - (C) dengan memasukkan selepas butiran “(DD) Codoxime” butiran “(DD) 1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45)”; dan
  - (D) dengan memasukkan selepas butiran “(DD) Diampromide” butiran yang berikut:

“(DD) 3,4-Dichloro-N-[(1-dimethylamino) cyclohexylmethyl]benzamide (AH-7921)

(DD) 3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide

(U-47700)”; dan

(ix) dalam senarai “**Miscellaneous**”—

- (A) dengan memasukkan selepas butiran “Afoxolaner” butiran “Albutrepenonacog alfa”;
- (B) dengan memasukkan selepas butiran “Amifostine, its salts; its esters” butiran “Amino acids, unless specified elsewhere in the List”;
- (C) dengan memasukkan selepas butiran “Anagrelide” butiran “4-Anilino-N-phenethylpiperidine (ANPP)”;
- (D) dengan memasukkan selepas butiran “Becaplermin” butiran “Berococog alfa”;
- (E) dengan memasukkan selepas butiran “Dinitrothymols” butiran “Diquafosol”;
- (F) dengan memasukkan selepas butiran “Eltrombopag” butiran “Eprinomectin”;
- (G) dengan memasukkan selepas butiran “Glucagon; its salts” butiran “Glucose”;

(H) dengan memasukkan selepas butiran “Hydrogen cyanide; metal cyanides other than ferrocyanides and ferricyanides” butiran “Hydroxyethylstarch”;

(I) dengan memasukkan selepas butiran “Metyrapone; its salts” butiran yang berikut:

“Minerals; the following, unless specified elsewhere in the List:

Chromium

Copper

Fluorine

Iron

Manganese

Selenium

Zinc”;

(J) dengan memasukkan selepas butiran “Pentosan” butiran yang berikut:

“N-Phenethyl-4-piperidinone (NPP)

Phenolphthalein”;

(K) dengan memasukkan selepas butiran “Stavesacre; alkaloids of” butiran “Succinylated gelatin”;

- (L) dengan memasukkan selepas butiran “Triflusal” butiran “Triglycerides”; dan
- (M) dalam butiran “Vitamin; the following:” dengan memasukkan selepas butiran “Mecobalamin” butiran “Menaquinone”.

Dibuat 18 Disember 2018  
[KKM.R.600-1/1/56; PN(PU2)172/XII]

DATUK SERI DR. DZULKEFLY BIN AHMAD  
*Menteri Kesihatan*

## POISONS ACT 1952

## POISONS (AMENDMENT OF POISONS LIST) ORDER 2019

IN exercise of the powers conferred by section 6 of the Poisons Act 1952 [*Act 366*], the Minister, after consultation with the Poisons Board, makes the following order:

**Citation**

1. This order may be cited as the **Poisons (Amendment of Poisons List) Order 2019**.

**Amendment of First Schedule**

2. The Poisons Act 1952 is amended in the First Schedule—

*(a)* in the Poisons List—

- (i) by inserting after the item “Adalimumab” and the particulars relating to it the following items:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-APINACA)	-	All preparations				
N-(Adamantan-1-yl)-1-pentyl-1H-indazole-3-carboxamide (APINACA)	-	All preparations”;				

(ii) by inserting after the item “Agomelatine” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Albutrepenonacog alfa	-	All preparations”;				

(iii) by inserting after the item “Amilsulpride” and the particulars relating to it the following items:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Amino acids, unless specified elsewhere in the List	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C
N- [(1S) - 1- (Aminocarbonyl) - 2- methylpropyl] - 1- (cyclohexylmethyl) 1H- indazole- 3- carboxamide (AB-CHMINACA)	-	All preparations”;				

(iv) by inserting after the item “Anidulafungin” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“4-Anilino-N-phenethylpiperidine (ANPP)	-	-	-	-	All preparations”;	

(v) by inserting after the item “Atenolol; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Atezolizumab	-	All preparations”;				

(vi) by inserting after the item “Bepridil; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Beroctocog alfa	-	All preparations”;				

(vii) by inserting after the item “Carfentanil citrate” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Carfilzomib	-	All preparations”;				

(viii) by inserting after the item “Cyclofenil” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"N-[[1-(Cyclohexylmethyl)-1H-indol-3yl]carbonyl]-3-methyl-L-valinate (MDMB-CHMICA)	-	All preparations";				

(ix) by inserting after the item "Dapsone" and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Daratumumab	-	All preparations";				

(x) by inserting after the item "Dipyron" and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Diquafosol	-	All preparations";				

(xi) by inserting after the item “Elaterin” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Elbasvir	-	All preparations”;				

(xii) by inserting after the item “Emepromium; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Emodepside	-	-	All preparations”;			

(xiii) by inserting after the item “Eplerenone” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Eprinomectin	-	All preparations”;				

(xiv) by inserting after the item “N-ethyl MDA (DD)” and the particulars relating to it the following items:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Ethylone (3,4-Methylenedioxy-N-ethylcathinone)	-	All preparations				
Ethylphenidate	-	All preparations”;				

(xv) by inserting after the item “[1-(5-fluoropentyl)-1H-indol-3-yl](naphthalen-1-yl) methanone (AM-2201)” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“[1-(5-Fluoropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl) methanone (XLR-11)	-	All preparations”;				

(xvi) by inserting after the item “Glucagon; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Glucose	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”;

(xvii) by inserting after the item “Granisetron; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Grazoprevir	-	All preparations”;				

(xviii) by inserting after the item “8-[N-(2-hydroxyethyl)-methyl- amino]-1, 3, 7 trimethylxanthine” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Hydroxyethylstarch	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”;

(xix) by substituting for the item “Iodine” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Iodine	-	-	All preparations for parenteral administration. All medicinal preparations containing 2% and above of iodine	All preparations unless in Group C or exempted	-	Preparations containing less than 2% of iodine unless in Group C”;

(xx) by inserting after the item “Methimazole; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Methiopropamine (MPA)	-	All preparations”;				

(xxi) by inserting after the item “Methotrexate; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Methoxetamine (MXE)	-	All preparations”;				

(xxii) by inserting after the item “N-Methylephedrine camsylate” and the particulars relating to it the following items:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“4-Methylethcathinone (4-MEC)	-	All preparations				

3- Methylmethcathinone - All preparations  
(3-MMC)

Methyl 2-([1-(5-fluoropentyl)-  
1H-indazol-3-yl]  
carbonyl}amino)-3-  
methylbutanoate (5F-AMB) - All preparations”;

(xxiii) by inserting after the item “Miltefosine” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Minerals; the following, unless specified elsewhere in the List: Chromium Copper Fluorine Iron Manganese Selenium Zinc	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”;

(xxiv) in the item “Narcotic substances, the following: their isomers (whenever the existence of such isomers is possible within the specific chemical designation); their salts; their esters and ethers (whenever the existence of such esters or ethers is possible); the salts of their esters and ethers –” —

(A) by inserting after the item “(DD) Acetyldihydrocodeine” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) Acetylfentanyl	-	All preparations”;				

(B) by substituting for the item “(DD) 4-bromo-2,5-dimethoxyphenylethylamine (2C-B)” and the particulars relating to it the following items:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) 4-bromo-2,5-dimethoxyphenethylamine (2C-B)	All	preparations				

(DD) Butyrfentanyl - All preparations”;

(C) by inserting after the item “(DD) Codoxime” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) 1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45)	-	All preparations”;				

(D) by inserting after the item “(DD) Diampromide” and the particulars relating to it the following items:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) 3,4-Dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide (AH-7921)	-	All preparations				

(DD) 3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700) - All preparations”;

(E) by substituting for the item “(DD) Remifentanyl” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
“(DD) Remifentanyl	-	All products registered under the Control of Drugs and Cosmetics Regulations 1984”;					

(xxv) by inserting after the item “Nebivolol” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Necitumumab	-	All preparations;				

(xxvi) by inserting after the item “Nialamide” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Nicarbazin	-	“All preparations”;				

(xxvii) by inserting after the item “Oseltamivir” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Osimertinib	-	All preparations”;				

(xxviii) by inserting after the item “Paramethoxyamphetamine (PMA) (DD)” and the particulars relating to it the following items:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Para-methoxymethylamphetamine (PMMA) (DD)	-	All preparations				
Para-methyl-4-methylaminorex (4,4'-DMAR)	-	All preparations”;				

(xxix) by inserting after the item “Pentazocine; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Pentedrone (α-methylaminovalerophenone)	-	All preparations”;				

(xxx) by inserting after the item “Phenethylamine” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“N-Phenethyl-4-piperidinone (NPP)	-	-	-	-	All preparations”;	

(xxxi) by inserting after the item “Phenmetrazine; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Phenolphthalein	-	-	All preparations for therapeutic use	-	All preparations unless in Group C”;	

(xxxii) by inserting after the item “Pyrovalerone” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“ $\alpha$ -Pyrrolidinovalerophenone ( $\alpha$ -PVP)	-	All preparations”;				

(xxxiii) by inserting after the item “Quinine; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F-PB-22)	-	All preparations”;				

(xxxiv) by inserting after the item “Rizatriptan; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Robenidine	-	All preparations”;				

(xxxv) by inserting after the item “Styramate” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Succinylated gelatin	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”;

(xxxvi) by inserting after the item “Triflusal” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Triglycerides	-	-	All preparations for parenteral	-	-	All preparations

administration

unless in Group C”;

(xxxvii) in the item “Vitamins, the following:”, by inserting after the item “Mecobalamin” and the particulars relating to it the item “Menaquinone”; and

(b) in the Appendix to the Poisons List—

(i) in the list of “**Anaesthetics**” by inserting after the item “Local anaesthetics, the following: their salts; their homologues and analogues; their molecular compounds” the item “Methoxetamine (MXE)”;

(ii) in the list of “**Analeptics and Central Stimulants**”—

(A) by inserting after the item “N-Ethyl MDA (DD)” the following items:

“Ethylone (3,4-Methylenedioxy-N-ethylcathinone)  
Ethylphenidate”;

(B) by inserting after the item “Methcathinone (DD)” the item “Methiopropamine (MPA)”;

(C) by inserting after the item “3, 4-Methylenedioxymetamphetamine (MDMA) (DD)” the following items:

“4-Methylethcathinone (4-MEC)  
3-Methylmethcathinone (3-MMC)”;

(D) by inserting after the item “Paramethoxyamphetamine (PMA) (DD)” the following items:

“Para-methoxymethylamphetamine (PMMA) (DD)  
Para-methyl-4-methylaminorex (4,4'-DMAR)”;

(E) by inserting after the item “Pemoline; its salts” the item “Pentedrone ( $\alpha$ -methylaminovalerophenone)”; and

(F) by inserting after the item “Pyrovalerone” the item “ $\alpha$ -Pyrrolidinovalerophenone ( $\alpha$ -PVP)”;

(iii) in the list of **“Analgesics including antipyretic and anti-inflammatory agents”**—

(A) by inserting after the item “Acetanilide; alkylacetanilides” the following items:

“N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-APINACA)  
N-(Adamantan-1-yl)-1-pentyl-1H-indazole-3-carboxamide (APINACA)”;

- (B) by inserting after the item “Amidopyrine; its salts” the item “N- [(1S) - 1- (Aminocarbonyl) - 2- methylpropyl] - 1- (cyclohexylmethyl) 1H- indazole- 3- carboxamide (AB-CHMINACA)”;
- (C) by inserting after the item “Cinchophen and other substances structurally derived from 4 quinolinecarboxylic acid unless specified elsewhere in the List; their salts and esters” the item “N-{{[1-(Cyclohexylmethyl)-1H-indol-3yl]carbonyl}-3-methyl-L-valinate (MDMB-CHMICA)”;
- (D) by inserting after the item “Flunixin” the item “[1-(5-Fluoropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl) methanone (XLR-11)”;
- (E) by inserting after the item “Mesalazine” the item “Methyl 2-({[1-(5-fluoropentyl)-1H-indazol-3-yl] carbonyl}amino)-3-methylbutanoate (5F-AMB)”;
- (F) by inserting after the item “Proquazone” the item “Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3- carboxylate (5F-PB-22)”;
- (iv) in the list of “**Anthelmintics**”, by inserting after the item “Doramectin” the item “Emodepside”;
- (v) in the list of “**Antifungals and Antiprotozoals**”—
- (A) by inserting after the item “Natamycin” the item “Nicarbazin”; and

(B) by inserting after the item “Posaconazole” the item “Robenidine”;

(vi) in the list of “**Antineoplastic agents and Immunosuppressants**”—

(A) by inserting after the item “L-Asparaginase” the item “Atezolizumab”;

(B) by inserting after the item “Carboplatin” the item “Carfilzomib”;

(C) by inserting after the item “Dacliximab” the item “Daratumumab”;

(D) by inserting after the item “Natalizumab” the item “Necitumumab”; and

(E) by inserting after the item “Orthopterin” the item “Osimertinib”;

(vii) in the list of “**Antiviral agents**”—

(A) by inserting after the item “Efavirenz” the item “Elbasvir”; and

(B) by inserting after the item “Ganciclovir” the item “Grazoprevir”;

(viii) in the list of “**Narcotics**” —

- (A) by inserting after the item “(DD) Acetyldihydrocodeine” the item “(DD) Acetylfentanyl”;
- (B) by inserting after the item “(DD) 4-bromo-2, 5-dimethoxyphenylethylamine (2C-B)” the item “(DD)Butyrfentanyl”;
- (C) by inserting after the item “(DD) Codoxime” the item “(DD) 1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45)”; and
- (D) by inserting after the item “(DD) Diampromide” the following items:
  - “(DD) 3,4-Dichloro-N-[(1-dimethylamino) cyclohexylmethyl]benzamide (AH-7921)
  - “(DD) 3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700)”; and

(ix) in the list of “**Miscellaneous**”—

- (A) by inserting after the item “Afoxolaner” the item “Albutrepenonacog alfa”;

- (B) by inserting after the item “Amifostine; its salts; its esters” the item “Amino acids, unless specified elsewhere in the List”;
- (C) by inserting after the item “Anagrelide” the item “4-Anilino-N-phenethylpiperidine (ANPP)”;
- (D) by inserting after the item “Becaplermin” the item “Beroctocog alfa”;
- (E) by inserting after the item “Dinitrothymols” the item “Diquafosol”;
- (F) by inserting after the item “Eltrombopag” the item “Eprinomectin”;
- (G) by inserting after the item “Glucagon; its salts” the item “Glucose”;
- (H) by inserting after the item “Hydrogen cyanide; metal cyanides other than ferrocyanides and ferricyanides” the item “Hydroxyethylstarch”;
- (I) by inserting after the item “Metyrapone; its salts” the following item:

“Minerals; the following, unless specified elsewhere in the List:

Chromium

Copper

Fluorine

Iron  
Manganese  
Selenium  
Zinc”;

(J) by inserting after the item “Pentosan” the following items:

“N-Phenethyl-4-piperidinone (NPP)  
Phenolphthalein”;

(K) by inserting after the item “Stavesacre, alkaloids of” the item “Succinylated gelatin”;

(L) by inserting after the item “Triflusal” the item “Triglycerides”; and

(M) in the item “Vitamin; the following:” by inserting after the item “Mecobalamine” the item “Menaquinone”.

Made 18 December 2018  
[KKM.R.600-1/1/1/56; PN(PU2)172/XII]

DATUK SERI DR. DZULKEFLY BIN AHMAD  
*Minister of Health*